114872-59-2

Upstream product

• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 89751-95-1 para-(trifluoromethyl)benzyl acetate 
• 6140-17-6 4-methylbenzotrifluoride 
• 105-53-3 diethyl malonate 

Downstream Products

• 82337-58-4 2-acetamido-3-(4-(trifluoromethyl)phenyl)propanoic acid 
• 153181-04-5 2-Acetylamino-2-(4-trifluoromethyl-benzyl)-malonic acid monoethyl ester 
• 247113-86-6 C₂₅H₂₀F₃NO₄ 
• 3832-75-5 (S)-4-trifluoromethylphenylalanine 
• 82317-77-9 methyl (R)-2-acetamido-3-(4-(trifluoromethyl)phenyl)propanoate 
• 82317-73-5 2-Acetylamino-3-(4-trifluoromethyl-phenyl)-propionic acid methyl ester 
• 3832-77-7 (R)-2-Amino-3-(4-trifluoromethyl-phenyl)-propionic acid; hydrochloride 
• 82317-83-7 (R)-2-((tert-butoxycarbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propanoic acid 
• 153181-05-6 2-Acetylamino-3-(4-trifluoromethyl-phenyl)-propionic acid ethyl ester 
• 114926-34-0 (S)-2-Acetylamino-3-(4-trifluoromethyl-phenyl)-propionic acid 
• 153181-07-8 (S)-2-amino-3-(4-(trifluoromethyl)phenyl)propan-1-ol 
• 167496-29-9 N-t-BOC-4-(trifluoromethyl)phenylalanine 

Relevant academic research and scientific papers

Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension

Phosphodiesterase 5 (PDE5) inhibitors have been used as clinical agents to treat erectile dysfunction and pulmonary arterial hypertension (PAH). Herein, we detail the discovery of a novel series of chromeno[2,3-c]pyrrol-9(2H)-one derivatives as selective and orally bioavailable inhibitors against phosphodiesterase 5. Medicinal chemistry optimization resulted in 2, which exhibits a desirable inhibitory potency of 5.6 nM with remarkable selectivity as well as excellent pharmacokinetic properties and an oral bioavailability of 63.4%. In addition, oral administration of 2 at a dose of 5.0 mg/kg caused better pharmacodynamics effects on both mPAP (mean pulmonary artery pressure) and RVHI (index of right ventricle hypertrophy) than sildenafil citrate at a dose of 10.0 mg/kg. These activities along with its reasonable druglike properties, such as human liver microsomal stability, cytochrome inhibition, hERG inhibition, and pharmacological safety, indicate that 2 is a potential candidate for the treatment of PAH.

Use of acetate as a leaving group in palladium-catalyzed nucleophilic substitution of benzylic esters

The palladium complex prepared in situ from [Pd(η3-C3H5)(cod)]BF4 and bidentate phosphine DPPF was a good catalyst for the nucleophilic substitution of benzyl acetate. Significant acceleration of the palladium-catalyzed substitution was observed when an alcohol was employed as a reaction solvent. The palladium catalyst was effective for the benzylation of various stabilized carbanions, amines, and benzenesulfinate with benzylic acetates.

Synthetic and biotransformation studies on prochiral non-proteinogenic amino acids: Diethyl α-acetamido, α-alkylmalonates

Nine diethyl α-acetamido, α-alkylmalonates 3-11 (alkyl=methyl, benzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2,6-difluorobenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyi, 2-chlorobenzyl and 3-chlorobenzyl) have been synthesised in three steps starting with diethyl malonate in overall yields of 49-90%. The structures of C-alkylated acetamidomalonates have been established on the basis of their speciral data, the structures of two compounds 9 and 11 are also confirmed on the basis of their X-ray crystallographic studies. Further, the X-ray crystal structure of the chiral monoethyl ester of α-acetamidomalonic acid 1 has been studied. None of our C-alkylated acetamidomalonate has been found to be a substrate for lipase-catalysed enantiodifferentiating deesterification/hydrolysis of the symmetric diester groups.